Skip to main content
SpringerLink
Log in

Zytoreduktive Prostatektomie und Metastasektomie beim metastasierten Prostatakarzinom

  • Chapter
  • First Online:
Metastasiertes Prostatakarzinom

  • 212 Accesses

Zusammenfassung

Trotz der zunehmenden Wahrnehmung von Früherkennungsprogrammen weisen auch heute noch ca. 10 % der neu diagnostizierten Prostatakarzinome systemische Metastasen auf. Bisher galt das Dogma, dass eine lokale Therapie des Primarius bei Vorliegen von Fernmetastasen nicht indiziert ist. Auch die lokale Therape von insolierten Metastasen wurde als nicht sinnvoll erachtet. Diese Einschätzung hat sich in den vergangenen Jahren aufgrund propektiver und retrospektiver Studien geändert. Das vorliegende Kapitel reflektiert die aktuelle Evidenzlage.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 59.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 74.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Literatur

  • Antwi S, Everson TM (2014) Prognostic impact of definitive local therapy of the primary tumor in men with metastatic prostate cancer at diagnosis: a population-based, propensity score analysis. Cancer Epidemiol 38:435–441

    Article  PubMed  Google Scholar 

  • Armstrong AJ, Azad AA, Iguchi T, Szmulewitz RZ, Petrylak DP, Holzbeierlein J, Villers A, Alcaraz A, Alekseev B, Shore ND et al (2022) Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer. J Clin Oncol 40:1616–1622

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Babst C, Amiel T, Maurer T, Knipper S, Lunger L, Tauber R, Retz M, Herkommer K, Eiber M, von Amsberg G et al (2022) Cytoreductive radical prostatectomy after chemohormonal therapy in patients with primary metastatic prostate cancer. Asian J Urol 9:69–74

    Article  PubMed  Google Scholar 

  • Battaglia A, Devos G, Decaestecker K et al (2019) Metastasectomy for visceral and skeletal oligorecurrent prostate cancer. World J Urol 37:1543–1549

    Article  PubMed  Google Scholar 

  • Buelens S, Poelaert F, Claeys T, De Bleser E, Dhondt B, Verla W, Ost P, Rappe B, De Troyer B, Verbaeys C et al (2022) Multicentre, prospective study on local treatment of metastatic prostate cancer (LoMP study). BJU Int 129:699–707

    Article  CAS  PubMed  Google Scholar 

  • Chaloupka M, Stoermer L, Apfelbeck M, Buchner A, Wenter V, Stief CG, Westhofen T, Kretschmer A (2021) Health-related quality of life following cytoreductive radical prostatectomy in patients with de-novo oligometastatic prostate cancer. Cancers 13:5636

    Article  PubMed  PubMed Central  Google Scholar 

  • Chi KN, Chowdhury S, Bjartell A, Chung BH, Pereira de Santana Gomes AJ, Given R, Juárez A, Merseburger AS, Özgüroglu M, Uemura H et al (2021) Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN study. J Clin Oncol 39:2294–2303

    Google Scholar 

  • Chohan MO, Kahn S, Cederquist G, Reiner AS, Schwab J, Laufer I, Bilsky M (2018) Surgical decompression of high-grade spinal cord compression from hormone refractory metastatic prostate cancer. Neurosurgery 82(5):670–677

    Article  PubMed  Google Scholar 

  • Clarke NW, Ali A, Ingleby FC, Hoyle A, Amos CL, Attard G, Brawley CD, Calvert J, Chowdhury S, Cook A et al (2019) Addition of docetaxel to hormonal therapy in low-and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial. Ann Oncol 30:1992–2003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Ciriaco P, Briganti A, Bernabei A et al (2019) Safety and early oncologic outcomes of lung resection in patients with isolated pulmonary recurrent prostate cancer: a single-center experience. Eur Urol 75:871–874

    Article  PubMed  Google Scholar 

  • Culp SH, Schellhammer PF, Williams MB (2014) Might men diagnosed with metastatic prostate cancer benefit from definitive treatment of the primary tumor? A SEER-based study. Eur. Urol. 65:1058–1066

    PubMed  Google Scholar 

  • Dai B, Zhang S, Wan FN, Wang HK, Zhang JY, Wang QF, Kong YY, Ma XJ, Mo M, Zhu Y et al (2022) Combination of androgen deprivation therapy with radical local therapy versus androgen deprivation therapy alone for newly diagnosed oligometastatic prostate cancer: a phase ii randomized controlled trial. Eur Urol Oncol 5:519–525

    Article  PubMed  Google Scholar 

  • Davis ID, Martin AJ, Zielinski RR, Thomson A, Tan TH, Sandhu S, Reaume MN, Pook DW, Parnis F, North SA et al (2022) Updated overall survival outcomes in ENZAMET (ANZUP 1304), an international, cooperative group trial of enzalutamide in metastatic hormone-sensitive prostate cancer (mHSPC). J Clin Oncol 40(Suppl. S17), LBA5004

    Google Scholar 

  • Dearnaley D, Hinder V, Hijab A, Horan G, Srihari N, Rich P, Houston JG, Henry AM, Gibbs S, Venkitaraman R, Cruickshank C, Hassan S, Miners A, Mason M, Pedley I, Payne H, Brock S, Wade R, Robinson A, Din O, Lees K, Graham J, Worlding J, Murray J, Parker C, Griffin C, Sohaib A, Hall E (2022) PROMPTS investigators. Observation versus screening spinal MRI and pre-emptive treatment for spinal cord compression in patients with castration-resistant prostate cancer and spinal metastases in the UK (PROMPTS): an open-label, randomised, controlled, phase 3 trial. Lancet Oncol. Apr 23(4):501–513

    Google Scholar 

  • Fizazi K, Tran N, Fein L, Matsubara N, Rodriguez-Antolin A, Alekseev BY, Özgüroglu M, Ye D, Feyerabend S, Protheroe A et al (2019) Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castrationsensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial. Lancet Oncol 20:686–700

    Article  CAS  PubMed  Google Scholar 

  • Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P et al (2022a) Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 2 factorial design. Lancet 399:1695–1707

    Article  CAS  PubMed  Google Scholar 

  • Fizazi K, Foulon S, Carles J, Roubaud G, McDermott R, Fléchon A, Tombal B, Supiot S, Berthold D, Ronchin P, Kacso G, Gravis G, Calabro F, Berdah JF, Hasbini A, Silva M, Thiery-Vuillemin A, Latorzeff I, Mourey L, Laguerre B, Abadie-Lacourtoisie S, Martin E, El Kouri C, Escande A, Rosello A, Magne N, Schlurmann F, Priou F, Chand-Fouche ME, Freixa SV, Jamaluddin M, Rieger I, Bossi A (2022b) PEACE-1 investigators. Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet. Apr 30;399(10336):1695–1707

    Google Scholar 

  • Fossati N, Suardi N, Gandaglia G, Bravi CA, Soligo M, Karnes RJ, Shariat S, Battaglia A, Everaerts W, Joniau S, Van Poppel H, Rajarubendra N, Gill IS, Larcher A, Mottrie A, Schmautz M, Heidenreich A, Kalz A, Osmonov D, Juenemann KP, Herlemann A, Gratzke C, Stief C, Montorsi F, Briganti A (2019) Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large. Multi-institutional Analysis. Eur Urol 75(1):176–183

    PubMed  Google Scholar 

  • Gandaglia G, Fossati N, Stabile A, Bandini M, Rigatti P, Montorsi F, Briganti A (2017a) Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol 72:289–292

    Article  PubMed  Google Scholar 

  • Gandaglia G, Fossati N, Stabile A et al (2017b) Radical prostatectomy in men with oligometastatic prostate cancer: results of a single-institution series with long-term follow-up. Eur Urol 72:289–292

    Article  PubMed  Google Scholar 

  • Gravis G, Fizazi K, Joly F, Oudard S, Priou F, Esterni B, Latorzeff I, Delva R, Krakowski I, Laguerre B et al (2013) Androgendeprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial. Lancet Oncol 14:149–158

    Article  CAS  PubMed  Google Scholar 

  • Gratzke C, Engel J, Stief CG (2014) Role of radical prostatectomy in metastatic prostate cancer: data from the munich cancer registry. Eur Urol 66:602–603

    Article  PubMed  Google Scholar 

  • Guo X, Xia H, Su X, Hou H, Zhong Q, Wang J (2021) Comparing the survival outcomes of radical prostatectomy versus radiotherapy for patients with de novo metastasis prostate cancer: a population-based study. Front Oncol 11:797462

    Article  PubMed  PubMed Central  Google Scholar 

  • Hashmi SMM, Hammoud I, Kumar P, Sartaj AA, Ghosh K, Ray A, Golash A (2022) Outcome of surgical treatment for metastatic spinal cord compression: a single-center retrospective study. Asian J Neurosurg. 17(4):577–583

    Article  PubMed  PubMed Central  Google Scholar 

  • Heidenreich A, Fossati N, Pfister D, Suardi N, Montorsi F, Shariat S, Grubmüller B, Gandaglia G, Briganti A, Karnes RJ (2018) Cytoreductive radical prostatectomy in men with prostate cancer and skeletal metastases. Eur Urol Oncol 1:46–53

    Article  PubMed  Google Scholar 

  • Heidenreich A, Pfister D, Porres D (2015) Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study. J Urol 193:832–838

    Article  PubMed  Google Scholar 

  • Heidenreich A, Bludau M, Bruns C, Nestler T, Porres D, Pfister DJKP (2020) Pelvic exenteration surgery in patients with locally advanced castration-naïve and castration-resistant, symptomatic prostate cancer. BJU Int 126(3):342–349

    Article  PubMed  Google Scholar 

  • Heidenreich A, Moul JW, Shariat S, Karnes RJ (2016) Role of salvage lymph node dissection in prostate cancer. Curr Opin Urol 26(6):581–589

    Article  PubMed  Google Scholar 

  • Hussain M, Tangen CM, Berry DL, Higano CS, Crawford ED, Liu G, Wilding G, Prescott S, Kanaga Sundaram S, Small EJ, Dawson NA, Donnelly BJ, Venner PM, Vaishampayan UN, Schellhammer PF, Quinn DI, Raghavan D, Ely B, Moinpour CM, Vogelzang NJ, Thompson IM Jr (2013) Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med Apr 4;368(14):1314–1325

    Google Scholar 

  • Jin K, Qiu S, Jin H, Zheng X, Zhou X, Jin D, Li J, Yang L, Wei Q (2020a) Survival outcomes for metastatic prostate cancer patients treated with radical prostatectomy or radiation therapy: a SEER-based study. Clin Genitourin Cancer 18:e705–e722

    Article  PubMed  Google Scholar 

  • Jin S, Wei J, Wang J, Wang B, Wu J, Gan H, Dai B, Qin X, Lin G, Wei Y et al (2020b) Prognostic value of local treatment in prostate cancer patients with different metastatic sites: a population based retrospective study. Front Oncol 10:527952

    Article  PubMed  PubMed Central  Google Scholar 

  • Kim IY, Mitrofanova A, Panja S, Sterling J, Srivastava A, Kim J, Kim S, Singer EA, Jang TL, Ghodoussipour S et al (2022) Genomic analysis and long-term outcomes of a phase 1 clinical trial on cytoreductive radical prostatectomy. Prostate Int. 10:75–79

    Article  PubMed  PubMed Central  Google Scholar 

  • Knipper S, Beyer B, Mandel P, Tennstedt P, Tilki D, Steuber T, Graefen M (2020) Outcome of patients with newly diagnosed prostate cancer with low metastatic burden treated with radical prostatectomy: a comparison to STAMPEDE arm H. World J Urol 38:1459–1464

    Article  CAS  PubMed  Google Scholar 

  • Kyriakopoulos CE, Chen YH, Carducci MA, Liu G, Jarrard DF, Hahn NM, Shevrin DH, Dreicer R, Hussain M, Eisenberger M et al (2018) Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial. J Clin Oncol 36:1080–1087

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lumen N, De Bleser E, Buelens S, Verla W, Poelaert F, Claeys W, Fonteyne V, Verbeke S, Villeirs G, De Man K et al (2021) The role of cytoreductive radical prostatectomy in the treatment of newly diagnosed low-volume metastatic prostate cancer. Results from the local treatment of metastatic prostate cancer (LoMP) Registry. Eur Urol Open Sci 29:68–76

    Google Scholar 

  • Mandel PC, Huland H, Tiebel A, Haese A, Salomon G, Budäus L, Tilki D, Chun F, Heinzer H, Graefen M et al (2021) Enumeration and changes in circulating tumor cells and their prognostic value in patients undergoing cytoreductive radical prostatectomy for oligometastatic prostate cancer-translational research results from the prospective ProMPT trial. Eur Urol Focus 7:55–62

    Article  PubMed  Google Scholar 

  • Mistretta FA, Luzzago S, Conti A, Verri E, Marvaso G, Collà Ruvolo C, Catellani M, Di Trapani E, Cozzi G, Bianchi R et al (2022) Oligometastatic prostate cancer: a comparison between multimodality treatment vs. androgen deprivation therapy alone. Cancers 14:2313

    Google Scholar 

  • Moschini M, Morlacco A, Kwon E, Rangel LJ, Karnes RJ (2017) Treatment of M1a/M1b prostate cancer with or with out radical prostatectomy at diagnosis. Prostate Cancer Prostatic Dis 20:117–121

    Article  CAS  PubMed  Google Scholar 

  • Ogunbona OB, Goodman AL, Osunkoya AO (2021) Metastatic prostatic adenocarcinoma to the brain and spinal cord: a contemporary clinicopathologic analysis of 30 cases. Int J Clin Exp Pathol 14:45–53

    CAS  PubMed  PubMed Central  Google Scholar 

  • Parker CC, James ND, Brawley CD, Clarke NW, Hoyle AP, Ali A, Ritchie AWS, Attard G, Chowdhury S, Cross W et al (2018) Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomized controlled phase 3 trial. Lancet 392:2353–2366

    Article  PubMed  PubMed Central  Google Scholar 

  • Parikh RR, Byun J, Goyal S, Kim IY (2017) Local therapy improves overall survival in patients with newly diagnosed metastatic prostate cancer. Prostate 77:559–572

    Article  PubMed  Google Scholar 

  • Ploussard G, Grabia A, Beauval JB, Barret E, Brureau L, Dariane C, Fiard G, Fromont G, Gauthé M, Mathieu R et al (2021) A 5-year contemporary nationwide evolution of the radical prostatectomy landscape. Eur Urol Open Sci 34:1–4

    Article  PubMed  PubMed Central  Google Scholar 

  • Poelaert F, Verbaeys C, Rappe B, Kimpe B, Billiet I, Plancke H, Decaestecker K, Fonteyne V, Buelens S, Lumen N (2017) Cytoreductive prostatectomy for metastatic prostate cancer: first lessons learned from the multicentric prospective local treatment of metastatic prostate cancer (LoMP) Trial. Urology 106:146–152

    Article  PubMed  Google Scholar 

  • Rajwa P, Yanagisawa T, Gruber M, Heidenreich A, Joniau S, Briganti A, Shariat SF, Marra G, Gandaglia G (2022) Surgical metastasectomy for visceral and bone prostate cancer metastases: a mini-review. Eur Urol Focus S2405–4569(22):00241–00243

    Google Scholar 

  • Rigatti P, Suardi N, Briganti A, Da Pozzo LF, Tutolo M, Villa L, Gallina A, Capitanio U, Abdollah F, Scattoni V, Colombo R, Freschi M, Picchio M, Messa C, Guazzoni G, Montorsi F (2011) Pelvic/retroperitoneal salvage lymph node dissection for patients treated with radical prostatectomy with biochemical recurrence and nodal recurrence detected by [11C]choline positron emission tomography/computed tomography. Eur Urol 60(5):935–943

    Article  PubMed  Google Scholar 

  • Satkunasivam R, Kim AE, Desai M, Nguyen MM, Quinn DI, Ballas L, Lewinger JP, Stern MC, Hamilton AS, Aron M et al (2015) Radical prostatectomy or external beam radiation therapy vs no local therapy for survival benefit in metastatic prostate cancer: a SEER-medicare analysis. J Urol 194:378–385

    Article  PubMed  PubMed Central  Google Scholar 

  • Sooriakumaran P, Wilson C, Rombach I, Hassanali N, Aning J, D Lamb A, Cathcart P, Eden C, Ahmad I, Rajan P et al (2022) Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: the testing radical prostatectomy in men with prostate cancer and oligo-metastases to the bone (TRoMbone) trial. BJU Int 130:43–53

    Google Scholar 

  • Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á et al (2022a) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med 386:1132–1142

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B (2022b) ARASENS Trial investigators. Darolutamide and survival in metastatic, hormone-sensitive prostate cancer. N Engl J Med Mar 24;386(12):1132–1142

    Google Scholar 

  • Steuber T, Berg KD, Røder MA, Brasso K, Iversen P, Huland H, Tiebel A, Schlomm T, Haese A, Salomon G et al (2017) Does cytoreductive prostatectomy really have an impact on prognosis in prostate cancer patients with low-volume bone metastasis? Results from a prospective case-control study. Eur Urol Focus 3:646–649

    Article  PubMed  Google Scholar 

  • Stolzenbach LF, Deuker M, Collà-Ruvolo C, Nocera L, Tian Z, Maurer T, Steuber T, Tilki D, Briganti A, Saad F et al (2021) Radical prostatectomy improves survival in selected metastatic prostate cancer patients: a North American population-based study. Int J Urol 28:834–839

    Article  CAS  PubMed  Google Scholar 

  • Suardi N, Gandaglia G, Gallina A, Di Trapani E, Scattoni V, Vizziello D, Cucchiara V, Bertini R, Colombo R, Picchio M, Giovacchini G, Montorsi F, Briganti A (2015) Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years. Eur Urol 67(2):299–309

    Article  PubMed  Google Scholar 

  • Takagi K, Kawase M, Kato D, Kawase K, Takai M, Iinuma K, Nakane K, Hagiwara N, Yamada T, Tomioka M et al (2022) Robot-assisted radical prostatectomy for potential cancer control in patients with metastatic prostate cancer. Curr Oncol 29:2864–2870

    Article  PubMed  PubMed Central  Google Scholar 

  • Tzelepi V, Efstathiou E, Wen S, Troncoso P, Karlou M, Pettaway CA, Pisters LL, Hoang A, Logothetis CJ, Pagliaro LC (2011) Persistent, biologically meaningful prostate cancer after 1 year of androgen ablation and docetaxel treatment. J Clin Oncol 29(18):2574–2581

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wang Y, Qin Z, Wang Y, Chen C, Wang Y, Meng X, Song N (2018) The role of radical prostatectomy for the treatment of metastatic prostate cancer: a systematic review and meta-analysis. Biosci Rep 38:BSR20171379

    Google Scholar 

  • Won AC, Gurney H, Marx G, De Souza P, Patel MI (2013) Primary treatment of the prostate improves local palliation in men who ultimately develop castrate-resistant prostate cancer. BJU Int 112:E250–E255

    Article  PubMed  Google Scholar 

  • Xue P, Wu Z, Wang K, Gao G, Zhuang M, Yan M (2020) Oncological outcome of combining cytoreductive prostatectomy and metastasis-directed radiotherapy in patients with prostate cancer and bone oligometastases: a retrospective cohort study. Cancer Manag. Res. 12:8867–8873

    Article  PubMed  PubMed Central  Google Scholar 

  • Younsi A, Riemann L, Scherer M, Unterberg A, Zweckberger K (2020) Impact of decompressive laminectomy on the functional outcome of patients with metastatic spinal cord compression and neurological impairment. Clin Exp Metastasis 37(2):377–390

    Article  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Klinik für Urologie, Uro-Onkologie, roboter-assistierte und spezielle urologische Chirurgie, Uniklinik Köln, Deutschland

    Axel Heidenreich, Julian Heidenreich & David Pfister

Authors
  1. Axel Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Julian Heidenreich
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David Pfister
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Axel Heidenreich .

Editor information

Editors and Affiliations

  1. Klinik für Urologie, Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Deutschland

    Axel S. Merseburger

  2. Klinik für Urologie, Universitätsklinikum Schleswig-Holstein Campus Lübeck, Lübeck, Deutschland

    Marie C. Roesch

Rights and permissions

Reprints and permissions

Copyright information

© 2023 Der/die Autor(en), exklusiv lizenziert an Springer-Verlag GmbH, DE, ein Teil von Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Heidenreich, A., Heidenreich, J., Pfister, D. (2023). Zytoreduktive Prostatektomie und Metastasektomie beim metastasierten Prostatakarzinom. In: Merseburger, A.S., Roesch, M.C. (eds) Metastasiertes Prostatakarzinom. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-662-67297-6_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-662-67297-6_5

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-662-67296-9

  • Online ISBN: 978-3-662-67297-6

  • eBook Packages: Medicine (German Language)

Publish with us

Policies and ethics

Search

Navigation